GE HealthCare’s SOFIE deal highlights shift in PET competition
GE HealthCare acquired SOFIE Biosciences, a US contract manufacturer of F-18 tracers, to secure supply capacity and support its $500M revenue target for Flyrcado by 2028. The deal mirrors Siemens Healthineers' model and addresses GE's reliance on external manufacturers. SOFIE also produces tracers for Lantheus, a competitor soon to be acquired by Curium. Analyst Ashley Clarke notes the move reduces risk but may not significantly increase market share.
How this was made
The 30-second read
Why it matters
The acquisition positions GE HealthCare as a more integrated player in the PET market, potentially improving margins and revenue stability.
Market read
First‑report M&A news for a large U.S. listed health‑tech firm; likely to move the stock and influence the PET imaging sector.
What to watch
Regulatory approvals for the deal and the competitive response from Siemens Healthineers' PETNET network.
Background
GE HealthCare is expanding beyond scanner sales into radiopharmaceutical manufacturing to mitigate supply risk for short‑half‑life F‑18 tracers.
Ticker impact
GE HealthCare announced the acquisition of SOFIE Biosciences, a contract manufacturer of F-18 tracers, expanding its radiopharmaceutical supply chain.
likely upside as investors price in expanded radiopharma capabilities and new revenue streams.
First‑report M&A news for a large listed company; the acquisition addresses a strategic risk and targets $500 M revenue for Flyrcado by 2028.
Market effects
Strengthens the PET imaging and radiopharma sector by consolidating manufacturing capacity under a major scanner maker.
U.S. radiopharma supply chain may see tighter integration, affecting competitors like Siemens Healthineers and Lantheus.
Highlights a shift toward vertical integration in nuclear medicine worldwide.
Counterpoint
The acquisition could strain GE HealthCare's balance sheet if integration costs exceed expectations, limiting upside.
Key entities
- CompanyGE HealthCare
Medical imaging and diagnostics business of General Electric, ticker GEHC.
- CompanySOFIE Biosciences
U.S. contract manufacturer of F‑18 PET tracers.
